Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 17/20 | 1.00 |
| ▸ | DRD2 | P14416 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.97 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.97 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.97 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.97 |
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
| ▸ | RAB9A | P51151 | 1/20 | 0.66 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Abt-724 SCHEMBL29406160 | 1.00 | DRD4 (1.00) | DRD4DRD2KDM4EALDH1A1CYP3A4 | |
| Abt-724 SCHEMBL29634880 | 0.99 | DRD4 (1.00) | DRD4DRD2KDM4EALDH1A1CYP3A4 | |
| Abt-724 SCHEMBL6316908 | 0.99 | DRD4 (1.00) | DRD4DRD2KDM4EALDH1A1CYP3A4 | |
| Abt-724 SCHEMBL6317285 | 0.92 | DRD4 (0.85) | DRD4DRD2KDM4EALDH1A1CYP3A4 | |
| Abt-724 SCHEMBL6325676 | 0.92 | DRD4 (0.85) | DRD4DRD2KDM4EALDH1A1CYP3A4 | |
| Abt-724 SCHEMBL4807347 | 0.90 | DRD4 (0.81) | DRD4DRD2KDM4EALDH1A1CYP3A4 | |
| Abt-724 SCHEMBL4807361 | 0.90 | DRD4 (0.81) | DRD4DRD2KDM4EALDH1A1CYP3A4 | |
| Abt-724 SCHEMBL6551097 | 0.89 | DRD4 (0.80) | DRD4DRD2KDM4EALDH1A1CYP3A4 | |
| SCHEMBL6096279 | 0.87 | DRD4 (0.76) | DRD4DRD2KDM4EALDH1A1CYP3A4 | |
| SCHEMBL4809160 | 0.87 | DRD4 (1.00) | DRD4DRD2KDM4EALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 149 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1373220-B1 | BENZIMIDAZOLES THAT ARE USEFUL IN TREATING SEXUAL DYSFUNCTION | ABBOTT LAB (US) | 2007-05-30 | — | — | EP | claimed |
| US-7022728-B2 | Benzimidazoles that are useful in treating male sexual dysfunction | ABBOTT LABORATORIES (US) | 2006-04-04 | — | — | US | claimed |
| US-6960589-B2 | Benzimidazoles that are useful in treating sexual dysfunction | ABBOTT LABORATORIES (US) | 2005-11-01 | — | — | US | claimed |
| EP-1483258-A1 | BENZIMIDAZOLE-DERIVATIVES FOR THE TREATMENT OF SEXUAL DYSFUNCTION | Abbott Laboratories (US) | 2004-12-08 | — | — | EP | claimed |
| US-20040198734-A1 | 2-(4-Aryl or heteroaryl-piperazin-1-ylmethyl)-1H-indole derivatives interacting with the dopamine | PFIZER INC | 2004-10-07 | — | — | US | claimed |
| US-20040127504-A1 | Benzimidazoles that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2004-07-01 | — | — | US | claimed |
| US-20040116443-A1 | Dopamine D4 ligands for the treatment of novelty-seeking disorders | PFIZER INC | 2004-06-17 | — | — | US | claimed |
| US-20040110766-A1 | Benzimidazoles that are useful in treating sexual dysfunction | ABBVIE INC. | 2004-06-10 | — | — | US | claimed |
| EP-1373220-A1 | BENZIMIDAZOLES THAT ARE USEFUL IN TREATING SEXUAL DYSFUNCTION | ABBOTT LABORATORIES (US) | 2004-01-02 | — | — | EP | claimed |
| WO-2003076431-A1 | BENZIMIDAZOLE-DERIVATIVES FOR THE TREATMENT OF SEXUAL DYSFUNCTION | ABBOTT LABORATORIES (US) | 2003-09-18 | — | — | WO | claimed |
| US-20030162790-A1 | Benzimidazoles that are useful in treating sexual dysfunction | ABBVIE INC. | 2003-08-28 | — | — | US | claimed |
| US-20030158208-A1 | Dopamine D4 ligands for the treatment of novelty-seeking disorders | PFIZER INC. | 2003-08-21 | — | — | US | claimed |
| US-20030100757-A1 | 2-(4-aryl or heteroaryl-piperazin-1-ylmethyl)-1H-indole derivatives interacting with the dopamine D4 receptor | PFIZER INC. | 2003-05-29 | — | — | US | claimed |
| US-20030008878-A1 | Benzimidazoles that are useful in treating sexual dysfunction | ABOTT LABORATORIES | 2003-01-09 | — | — | US | claimed |
| US-20020169167-A1 | Benzimidazoles that are useful in treating sexual dysfunction | ABBVIE INC. | 2002-11-14 | — | — | US | claimed |
| US-20020169166-A1 | Benzimidazoles that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2002-11-14 | — | — | US | claimed |
| WO-2002088093-A1 | BENZIMIDAZOLES THAT ARE USEFUL IN TREATING SEXUAL DYSFUNCTION | ABBOTT LABORATORIES (US) | 2002-11-07 | — | — | WO | claimed |
| US-20020049209-A1 | Dopamine D4 ligands for the treatment of novelty-seeking disorders | PFIZER INC. | 2002-04-25 | — | — | US | claimed |
| EP-1177792-A2 | Dopamine D4 Ligands for the treatment of novelty-seeking disorders | Pfizer Products Inc. (US) | 2002-02-06 | — | — | EP | claimed |
| US-10568851-B2 | Compounds and methods of treating ocular disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2020-02-25 | — | — | US | disclosed |
| US-10426773-B2 | Systems pharmacology for treating ocular disorders | CASE WESTERN UNIVERSITY (US) | 2019-10-01 | — | — | US | disclosed |
| US-20190099420-A1 | SYSTEMS PHARMACOLOGY FOR TREATING OCULAR DISORDERS | CASE WESTERN UNIVERSITY | 2019-04-04 | — | — | US | disclosed |
| EP-2697206-B1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | ATIR HOLDING S A (LU) | 2019-04-03 | — | — | EP | disclosed |
| US-20190022091-A1 | METHOD OF TREATMENT FOR MENTAL DISORDERS | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2019-01-24 | — | — | US | disclosed |
| US-9988377-B2 | Small molecule inducers of GDNF as potential new therapeutics for neuropsychiatric disorders | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2018-06-05 | — | — | US | disclosed |
| US-20180071285-A1 | SYSTEMS PHARMACOLOGY FOR TREATING OCULAR DISORDERS | CASE WESTERN RESERVE UNIVERSITY | 2018-03-15 | — | — | US | disclosed |
| US-9827242-B2 | Method of treatment for mental disorders | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-11-28 | — | — | US | disclosed |
| US-9827242-B2 | Method of treatment for mental disorders | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-11-28 | — | — | US | disclosed |
| US-20160317474-A1 | Managing Visual Dysfunction or Loss of Vision for Diabetic Subjects | UNIV EMORY (US) | 2016-11-03 | — | — | US | disclosed |
| EP-1698620-B1 | BENZENE COMPOUNDS DISUBSTITUTED WITH CYCLIC GROUPS AT THE 1- AND 2-POSITIONS | EISAI R&D MAN CO LTD (JP) | 2016-09-28 | — | — | EP | disclosed |
| EP-2896624-B1 | Heterotricyclic compounds as serotonergic and/or dopaminergic agents and uses thereof | ATIR HOLDING S A (LU) | 2016-07-13 | — | — | EP | disclosed |
| EP-2896624-B1 | Heterotricyclic compounds as serotonergic and/or dopaminergic agents and uses thereof | ATIR HOLDING S A (LU) | 2016-07-13 | — | — | EP | disclosed |
| US-20160193205-A1 | METHOD OF TREATMENT FOR MENTAL DISORDERS | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2016-07-07 | — | — | US | disclosed |
| US-20160193205-A1 | METHOD OF TREATMENT FOR MENTAL DISORDERS | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2016-07-07 | — | — | US | disclosed |
| US-9353067-B2 | Heterocyclic compounds and uses thereof in the treatment of sexual disorders | ATIR HOLDING S.A. (LU) | 2016-05-31 | — | — | US | disclosed |
| US-20160129000-A1 | METHOD OF TREATMENT FOR MENTAL DISORDERS | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2016-05-12 | — | — | US | disclosed |
| US-20160129000-A1 | METHOD OF TREATMENT FOR MENTAL DISORDERS | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2016-05-12 | — | — | US | disclosed |
| EP-2142541-B1 | HETEROTRICYCLIC COMPOUNDS AS SEROTONERGIC AND/OR DOPAMINERGIC AGENTS AND USES THEREOF | ATIR HOLDING S A (LU) | 2016-03-30 | — | — | EP | disclosed |
| EP-2142541-B1 | HETEROTRICYCLIC COMPOUNDS AS SEROTONERGIC AND/OR DOPAMINERGIC AGENTS AND USES THEREOF | ATIR HOLDING S A (LU) | 2016-03-30 | — | — | EP | disclosed |
| US-9259423-B2 | Method of treatment for mental disorders | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2016-02-16 | — | — | US | disclosed |
| EP-2896624-A1 | Heterotricyclic compounds as serotonergic and/or dopaminergic agents and uses thereof | Atir Holding S.A. (LU) | 2015-07-22 | — | — | EP | disclosed |
| EP-2896624-A1 | Heterotricyclic compounds as serotonergic and/or dopaminergic agents and uses thereof | Atir Holding S.A. (LU) | 2015-07-22 | — | — | EP | disclosed |
| WO-2015095257-A2 | MANAGING VISUAL DYSFUNCTION OR LOSS OF VISION FOR DIABETIC SUBJECTS | EMORY UNIVERSITY (US) | 2015-06-25 | — | — | WO | disclosed |
| US-9034872-B2 | Heterocyclic compounds and uses thereof in the treatment of sexual disorders | ATIR HOLDING S.A. (LU) | 2015-05-19 | — | — | US | disclosed |
| US-9034872-B2 | Heterocyclic compounds and uses thereof in the treatment of sexual disorders | ATIR HOLDING S.A. (LU) | 2015-05-19 | — | — | US | disclosed |
| US-9034872-B2 | Heterocyclic compounds and uses thereof in the treatment of sexual disorders | ATIR HOLDING S.A. (LU) | 2015-05-19 | — | — | US | disclosed |
| US-20150056699-A1 | SMALL MOLECULE INDUCERS OF GDNF AS POTENTIAL NEW THERAPEUTICS FOR NEUROPSYCHIATRIC DISORDERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2015-02-26 | — | — | US | disclosed |
| US-20140296247-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | ATIR HOLDING S.A. | 2014-10-02 | — | — | US | disclosed |
| US-20140235562-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | CASE WESTERN RESERVE UNIVERSITY | 2014-08-21 | — | — | US | disclosed |
| US-20140107128-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | ATIR HOLDING S.A. | 2014-04-17 | — | — | US | disclosed |
| US-20140107128-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | ATIR HOLDING S.A. | 2014-04-17 | — | — | US | disclosed |
| US-20140107128-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | ATIR HOLDING S.A. | 2014-04-17 | — | — | US | disclosed |
| EP-2697206-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | Atir Holding S.A. (LU) | 2014-02-19 | — | — | EP | disclosed |
| EP-2233472-B1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | ATIR HOLDING S A (LU) | 2014-01-15 | — | — | EP | disclosed |
| EP-2233472-B1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | ATIR HOLDING S A (LU) | 2014-01-15 | — | — | EP | disclosed |
| US-8614319-B2 | Heterocyclic compounds and uses thereof in the treatment of sexual disorders | ATIR HOLDING S.A. (LU) | 2013-12-24 | — | — | US | disclosed |
| WO-2013063269-A2 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | CASE WESTERN RESERVE UNIVERSITY (US) | 2013-05-02 | — | — | WO | disclosed |
| US-20130072479-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | ATIR HOLDING S.A. (LU) | 2013-03-21 | — | — | US | disclosed |
| US-20130072479-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | ATIR HOLDING S.A. (LU) | 2013-03-21 | — | — | US | disclosed |
| US-20130072479-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | ATIR HOLDING S.A. (LU) | 2013-03-21 | — | — | US | disclosed |
| WO-2013028999-A1 | SMALL MOLECULE INDUCERS OF GDNF AS POTENTIAL NEW THERAPEUTICS FOR NEUROPSYCHIATRIC DISORDERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2013-02-28 | — | — | WO | disclosed |
| US-20130018056-A1 | METHOD OF TREATMENT FOR MENTAL DISORDERS | DAINIPPON SUMITOMO PHARMA CO., LTD. | 2013-01-17 | — | — | US | disclosed |
| US-20130018056-A1 | METHOD OF TREATMENT FOR MENTAL DISORDERS | DAINIPPON SUMITOMO PHARMA CO., LTD. | 2013-01-17 | — | — | US | disclosed |
| US-8349850-B2 | Heterocyclic compounds and uses thereof in the treatment of sexual disorders | ATIR HOLDING S.A. (LU) | 2013-01-08 | — | — | US | disclosed |
| US-8349850-B2 | Heterocyclic compounds and uses thereof in the treatment of sexual disorders | ATIR HOLDING S.A. (LU) | 2013-01-08 | — | — | US | disclosed |
| US-8349850-B2 | Heterocyclic compounds and uses thereof in the treatment of sexual disorders | ATIR HOLDING S.A. (LU) | 2013-01-08 | — | — | US | disclosed |
| EP-2010505-B1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | ATIR HOLDING S A (LU) | 2012-12-05 | — | — | EP | disclosed |
| EP-2010505-B1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | ATIR HOLDING S A (LU) | 2012-12-05 | — | — | EP | disclosed |
| WO-2012140642-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | ATIR HOLDING S.A. (LU) | 2012-10-18 | — | — | WO | disclosed |
| US-8258139-B2 | Method of treatment for mental disorders | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-09-04 | — | — | US | disclosed |
| US-8258139-B2 | Method of treatment for mental disorders | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-09-04 | — | — | US | disclosed |
| WO-2012063513-A1 | METHOD OF TREATMENT FOR MENTAL DISORDERS | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-05-18 | — | — | WO | disclosed |
| US-20120115879-A1 | METHOD OF TREATMENT FOR MENTAL DISORDERS | Sumitomo Pharma Co., Ltd. (JP) | 2012-05-10 | — | — | US | disclosed |
| US-20120115879-A1 | METHOD OF TREATMENT FOR MENTAL DISORDERS | Sumitomo Pharma Co., Ltd. (JP) | 2012-05-10 | — | — | US | disclosed |
| US-8168639-B2 | Heterotricyclic compounds as serotonergic and/or dopaminergic agents and uses thereof | ATIR HOLDING S.A. (LU) | 2012-05-01 | — | — | US | disclosed |
| US-8168639-B2 | Heterotricyclic compounds as serotonergic and/or dopaminergic agents and uses thereof | ATIR HOLDING S.A. (LU) | 2012-05-01 | — | — | US | disclosed |
| US-8168639-B2 | Heterotricyclic compounds as serotonergic and/or dopaminergic agents and uses thereof | ATIR HOLDING S.A. (LU) | 2012-05-01 | — | — | US | disclosed |
| EP-1848709-B1 | NOVEL SALT FORM OF A DOPAMINE AGONIST | PFIZER LTD (GB) | 2011-05-18 | — | — | EP | disclosed |
| CN-102040552-A | 1, 2-di (cyclic group) substituted benzene derivative | EISAI R&D MAN CO LTD | 2011-05-04 | — | — | CN | disclosed |
| US-7910734-B2 | Cell adhesion inhibitory action and cell infiltration inhibitory action; inflammatory, autoimmune diseases associated with adhesion and infiltration of leukocytes, inflammatory bowel disease, ulcerative colitis, Crohn's disease, irritable bowel syndrome, rheumatoid arthritis, psoriasis, multiple sclerosi | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-03-22 | — | — | US | disclosed |
| EP-2233472-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | Atir Holding S.A. (LU) | 2010-09-29 | — | — | EP | disclosed |
| EP-2233472-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | Atir Holding S.A. (LU) | 2010-09-29 | — | — | EP | disclosed |
| US-20100216807-A1 | HETEROCYCLIC COMPOUNDS AS SEROTONERGIC AND / OR DOPAMINERGIC AGENTS AND USES THEREOF | ATIR Holding S.A (LU) | 2010-08-26 | — | — | US | disclosed |
| US-20100216807-A1 | HETEROCYCLIC COMPOUNDS AS SEROTONERGIC AND / OR DOPAMINERGIC AGENTS AND USES THEREOF | ATIR Holding S.A (LU) | 2010-08-26 | — | — | US | disclosed |
| US-20100216807-A1 | HETEROCYCLIC COMPOUNDS AS SEROTONERGIC AND / OR DOPAMINERGIC AGENTS AND USES THEREOF | ATIR Holding S.A (LU) | 2010-08-26 | — | — | US | disclosed |
| CN-101068798-B | Salts and crystals of 1-cyclopropylmethyl-4- [2- (3,3,5, 5-tetramethylcyclohexyl) phenyl ] piperazine | EISAI R&D MAN CO LTD | 2010-05-12 | — | — | CN | disclosed |
| US-20100029671-A1 | Heterocyclic Compounds And Uses Thereof In The Treatment Of Sexual Disorders | ATIR HOLDING S.A. (LU) | 2010-02-04 | — | — | US | disclosed |
| US-20100029671-A1 | Heterocyclic Compounds And Uses Thereof In The Treatment Of Sexual Disorders | ATIR HOLDING S.A. (LU) | 2010-02-04 | — | — | US | disclosed |
| US-20100029671-A1 | Heterocyclic Compounds And Uses Thereof In The Treatment Of Sexual Disorders | ATIR HOLDING S.A. (LU) | 2010-02-04 | — | — | US | disclosed |
| EP-2142541-A2 | HETEROTRICYCLIC COMPOUNDS AS SEROTONERGIC AND/OR DOPAMINERGIC AGENTS AND USES THEREOF | Atir Holding S.A. (LU) | 2010-01-13 | — | — | EP | disclosed |
| CN-100526301-C | 1, 2-di (cyclic) substituted benzene compounds | EISAI R&D MAN CO LTD (JP) | 2009-08-12 | — | — | CN | disclosed |
| US-20090156589-A1 | 1,2-DI(CYCLIC GROUP)SUBSTITUTED BENZENE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-18 | — | — | US | disclosed |
| US-7498329-B2 | Salt form of dopamine agonist | PFIZER INC. (US) | 2009-03-03 | — | — | US | disclosed |
| US-20090005354-A1 | New Amino Derivatives and Their Use as Pharmaceuticals | PFIZER, INC. (US) | 2009-01-01 | — | — | US | disclosed |
| US-20080280914-A1 | Intravenous Formulations of Pde Inhibitors | BAYER HEALTHCARE AG (DE) | 2008-11-13 | — | — | US | disclosed |
| WO-2008117269-A2 | HETEROTRI CYCIII C COMPOUNDS AS SEROTONERGIC AND/OR DOPAMINERGIC AGENTS AND USES THEREOF | ATIR HOLDING S.A. (LU) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008117269-A2 | HETEROTRI CYCIII C COMPOUNDS AS SEROTONERGIC AND/OR DOPAMINERGIC AGENTS AND USES THEREOF | ATIR HOLDING S.A. (LU) | 2008-10-02 | — | — | WO | disclosed |
| US-7425554-B2 | 1,2-di(cyclic)substituted benzene compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-09-16 | — | — | US | disclosed |
| US-20080214622-A1 | Substituted Triazole Derivatives As Oxytocin Antagonists | BROWN ALAN DANIEL | 2008-09-04 | — | — | US | disclosed |
| EP-1753763-B1 | INDAZOLE AND INDOLONE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | PFIZER LTD (GB) | 2008-08-13 | — | — | EP | disclosed |
| US-7410971-B2 | 1,2-di(cyclic)substituted benzene compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-08-12 | — | — | US | disclosed |
| US-20080161566-A1 | Crystal and Salt of 1-Cyclopropylmethyl-4-[2-(3,3,5,5-Tetramethylcyclohexyl)Phenyl]Piperazine | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-07-03 | — | — | US | disclosed |
| CN-101175723-A | 1, 2-di (cyclic group) substituted benzene derivative | EISAI R&D MAN CO LTD (JP) | 2008-05-07 | — | — | CN | disclosed |
| US-7351828-B2 | Benzimidazoles that are useful in treating sexual dysfunction | ABBOTT LABORATORIES (US) | 2008-04-01 | — | — | US | disclosed |
| EP-1892238-A1 | 1, 2-DI(CYCLIC GROUP)SUBSTITUTED BENZENE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2008-02-27 | — | — | EP | disclosed |
| EP-1863484-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | Pfizer Limited (GB) | 2007-12-12 | — | — | EP | disclosed |
| CN-101068798-A | Salts and crystals of 1-cyclopropylmethyl-4- [ 2- (3,3,5, 5-tetramethylcyclohexyl) phenyl ] piperazine | EISAI R&D MAN CO LTD (JP) | 2007-11-07 | — | — | CN | disclosed |
| EP-1848709-A1 | NOVEL SALT FORM OF A DOPAMINE AGONIST | Pfizer Limited (GB) | 2007-10-31 | — | — | EP | disclosed |
| WO-2007110868-A2 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | ATIR HOLDING S.A. (LU) | 2007-10-04 | — | — | WO | disclosed |
| EP-1832580-A1 | CRYSTAL AND SALT OF 1-CYCLOPROPYLMETHYL-4-Ý2-(3,3,5,5)-TETRAMETHYLCYCLOHEXYL)PHENYL¨PIPERAZINE | Eisai R&D Management Co., Ltd. (JP) | 2007-09-12 | — | — | EP | disclosed |
| EP-1819690-A2 | CHROMAN COMPOUNDS | Pfizer Limited (GB) | 2007-08-22 | — | — | EP | disclosed |
| EP-1373220-B1 | BENZIMIDAZOLES THAT ARE USEFUL IN TREATING SEXUAL DYSFUNCTION | ABBOTT LAB (US) | 2007-05-30 | — | — | EP | disclosed |
| US-20070112002-A1 | 1,2-di(cyclic)substituted benzene compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-05-17 | — | — | US | disclosed |
| EP-1758862-A1 | AMINOPYRIDINE DERIVATIVES AS SELECTIVE DOPAMINE D3 AGONISTS | Pfizer Limited (GB) | 2007-03-07 | — | — | EP | disclosed |
| EP-1753763-A2 | INDAZOLE AND INDOLONE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | Pfizer Limited (GB) | 2007-02-21 | — | — | EP | disclosed |
| CN-1902170-A | 1, 2-di (cyclic) substituted benzene compounds | EISAI R&D MAN CO LTD (JP) | 2007-01-24 | — | — | CN | disclosed |
| US-20060281747-A1 | 1,2-di(cyclic) substituted benzene derivatives | EISAI R&D MANAGEMENT CO., LTD. | 2006-12-14 | — | — | US | disclosed |
| US-20060276465-A1 | 1,2-di(cyclic) substituted benzene compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-12-07 | — | — | US | disclosed |
| WO-2006100588-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | PFIZER LIMITED (GB) | 2006-09-28 | — | — | WO | disclosed |
| EP-1698620-A1 | BENZENE COMPOUNDS DISUBSTITUTED WITH CYCLIC GROUPS AT THE 1- AND 2-POSITIONS | Eisai Co., Ltd. (JP) | 2006-09-06 | — | — | EP | disclosed |
| US-20060183740-A1 | Novel salt form of a dopamine agonist | PFIZER INC | 2006-08-17 | — | — | US | disclosed |
| WO-2006082511-A1 | NOVEL SALT FORM OF A DOPAMINE AGONIST | PFIZER LIMITED (GB) | 2006-08-10 | — | — | WO | disclosed |
| WO-2006056850-A2 | CHROMAN COMPOUNDS | PFIZER LIMITED (GB) | 2006-06-01 | — | — | WO | disclosed |
| US-7022728-B2 | Benzimidazoles that are useful in treating male sexual dysfunction | ABBOTT LABORATORIES (US) | 2006-04-04 | — | — | US | disclosed |
| US-20050288270-A1 | New aminopyridine derivatives and their use as pharmaceuticals | PFIZER INC | 2005-12-29 | — | — | US | disclosed |
| WO-2005116027-A2 | INDAZOLE AND INDOLONE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | PFIZER LIMTED (GB) | 2005-12-08 | — | — | WO | disclosed |
| WO-2005115985-A1 | AMINOPYRIDINE DERIVATIVES AS SELECTIVE DOPAMINE D3 AGONISTS | PFIZER LIMITED (GB) | 2005-12-08 | — | — | WO | disclosed |
| US-20050267096-A1 | New indazole and indolone derivatives and their use pharmaceuticals | PFIZER INC | 2005-12-01 | — | — | US | disclosed |
| US-20050261291-A1 | 1,2-Di(cyclic)substituted benzene compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-24 | — | — | US | disclosed |
| US-6960589-B2 | Benzimidazoles that are useful in treating sexual dysfunction | ABBOTT LABORATORIES (US) | 2005-11-01 | — | — | US | disclosed |
| EP-1531813-A1 | USE OF COMPOUNDS FOR INCREASING SPERMATOZOA MOTILITY | Applied Research Systems ARS Holding N.V. (AN) | 2005-05-25 | — | — | EP | disclosed |
| EP-1483258-A1 | BENZIMIDAZOLE-DERIVATIVES FOR THE TREATMENT OF SEXUAL DYSFUNCTION | Abbott Laboratories (US) | 2004-12-08 | — | — | EP | disclosed |
| US-20040198734-A1 | 2-(4-Aryl or heteroaryl-piperazin-1-ylmethyl)-1H-indole derivatives interacting with the dopamine | PFIZER INC | 2004-10-07 | — | — | US | disclosed |
| US-20040127504-A1 | Benzimidazoles that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2004-07-01 | — | — | US | disclosed |
| US-20040116443-A1 | Dopamine D4 ligands for the treatment of novelty-seeking disorders | PFIZER INC | 2004-06-17 | — | — | US | disclosed |
| US-20040110766-A1 | Benzimidazoles that are useful in treating sexual dysfunction | ABBVIE INC. | 2004-06-10 | — | — | US | disclosed |
| WO-2004006916-A1 | USE OF COMPOUNDS FOR INCREASING SPERMATOZOA MOTILITY | APPLIED RESEARCH SYSTEMS ARS HOLDING NV (AN) | 2004-01-22 | — | — | WO | disclosed |
| EP-1373220-A1 | BENZIMIDAZOLES THAT ARE USEFUL IN TREATING SEXUAL DYSFUNCTION | ABBOTT LABORATORIES (US) | 2004-01-02 | — | — | EP | disclosed |
| WO-2003076431-A1 | BENZIMIDAZOLE-DERIVATIVES FOR THE TREATMENT OF SEXUAL DYSFUNCTION | ABBOTT LABORATORIES (US) | 2003-09-18 | — | — | WO | disclosed |
| US-20030162790-A1 | Benzimidazoles that are useful in treating sexual dysfunction | ABBVIE INC. | 2003-08-28 | — | — | US | disclosed |
| US-20030158208-A1 | Dopamine D4 ligands for the treatment of novelty-seeking disorders | PFIZER INC. | 2003-08-21 | — | — | US | disclosed |
| US-20030100757-A1 | 2-(4-aryl or heteroaryl-piperazin-1-ylmethyl)-1H-indole derivatives interacting with the dopamine D4 receptor | PFIZER INC. | 2003-05-29 | — | — | US | disclosed |
| US-6548502-B2 | Preventing disorder selected from pathological gambling, attention deficit disorder with hyperactivity disorder, substance addiction such as drug and alcohol and sex in a mammals by administering pyrido(1,2-a) pyrazine derivatives | PFIZER INC | 2003-04-15 | — | — | US | disclosed |
| US-20030008878-A1 | Benzimidazoles that are useful in treating sexual dysfunction | ABOTT LABORATORIES | 2003-01-09 | — | — | US | disclosed |
| US-20020169167-A1 | Benzimidazoles that are useful in treating sexual dysfunction | ABBVIE INC. | 2002-11-14 | — | — | US | disclosed |
| US-20020169166-A1 | Benzimidazoles that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2002-11-14 | — | — | US | disclosed |
| WO-2002088093-A1 | BENZIMIDAZOLES THAT ARE USEFUL IN TREATING SEXUAL DYSFUNCTION | ABBOTT LABORATORIES (US) | 2002-11-07 | — | — | WO | disclosed |
| US-20020049209-A1 | Dopamine D4 ligands for the treatment of novelty-seeking disorders | PFIZER INC. | 2002-04-25 | — | — | US | disclosed |
| EP-1177792-A2 | Dopamine D4 Ligands for the treatment of novelty-seeking disorders | Pfizer Products Inc. (US) | 2002-02-06 | — | — | EP | disclosed |
| EP-1177792-A2 | Dopamine D4 Ligands for the treatment of novelty-seeking disorders | Pfizer Products Inc. (US) | 2002-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (37 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029671-A1 | Heterocyclic Compounds And Uses Thereof In The Treatment Of Sexual Disorders | PDE5A, PDE3B, PDE3A | DRD4 45/4885DRD2 33/4885KDM4E 1507/4885 |
| US-20020049209-A1 | Dopamine D4 ligands for the treatment of novelty-seeking disorders | SLC6A3, DRD4, DRD2 | DRD4 2/4885DRD2 3/4885KDM4E 1116/4885 |
| US-20140235562-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | ALDH1A2, TXNRD2, TXNRD1 | DRD4 4558/4885DRD2 4341/4885KDM4E 4713/4885 |
| US-10426773-B2 | Systems pharmacology for treating ocular disorders | GRK1, MTNR1A, MTNR1B | DRD4 1879/4885DRD2 1042/4885KDM4E 4771/4885 |
| US-20180071285-A1 | SYSTEMS PHARMACOLOGY FOR TREATING OCULAR DISORDERS | GRK1, MTNR1A, MTNR1B | DRD4 1879/4885DRD2 1042/4885KDM4E 4771/4885 |
| US-20050288270-A1 | New aminopyridine derivatives and their use as pharmaceuticals | DRD2, DRD1, DRD3 | DRD4 5/4885DRD2 1/4885KDM4E 2165/4885 |
| US-20160193205-A1 | METHOD OF TREATMENT FOR MENTAL DISORDERS | DRD4, HTR4, SLC6A3 | DRD4 1/4885DRD2 6/4885KDM4E 826/4885 |
| US-20090156589-A1 | 1,2-DI(CYCLIC GROUP)SUBSTITUTED BENZENE DERIVATIVE | CCR10, H1-10, VCAM1 | DRD4 591/4885DRD2 746/4885KDM4E 2662/4885 |
| US-20070112002-A1 | 1,2-di(cyclic)substituted benzene compounds | CCR10, HRH3, HRH1 | DRD4 523/4885DRD2 554/4885KDM4E 3710/4885 |
| US-20060281747-A1 | 1,2-di(cyclic) substituted benzene derivatives | CCR10, H1-10, CXCL10 | DRD4 547/4885DRD2 768/4885KDM4E 2695/4885 |
| US-20190099420-A1 | SYSTEMS PHARMACOLOGY FOR TREATING OCULAR DISORDERS | GRK1, MTNR1A, MTNR1B | DRD4 1879/4885DRD2 1042/4885KDM4E 4771/4885 |
| US-20020169167-A1 | Benzimidazoles that are useful in treating sexual dysfunction | CYP19A1, CYP51A1, CYP17A1 | DRD4 2278/4885DRD2 2231/4885KDM4E 2948/4885 |
| US-20040127504-A1 | Benzimidazoles that are useful in treating sexual dysfunction | CYP19A1, CYP51A1, CYP17A1 | DRD4 2278/4885DRD2 2231/4885KDM4E 2948/4885 |
| US-20030158208-A1 | Dopamine D4 ligands for the treatment of novelty-seeking disorders | SLC6A3, DRD4, DRD2 | DRD4 2/4885DRD2 3/4885KDM4E 1116/4885 |
| US-20080214622-A1 | Substituted Triazole Derivatives As Oxytocin Antagonists | OXTR, PRLHR, KISS1R | DRD4 430/4885DRD2 191/4885KDM4E 1533/4885 |
| US-20030100757-A1 | 2-(4-aryl or heteroaryl-piperazin-1-ylmethyl)-1H-indole derivatives interacting with the dopamine D4 receptor | DRD2, DRD3, DRD4 | DRD4 3/4885DRD2 1/4885KDM4E 1798/4885 |
| US-10568851-B2 | Compounds and methods of treating ocular disorders | ALDH1A2, TXNRD2, TXNRD1 | DRD4 4558/4885DRD2 4341/4885KDM4E 4713/4885 |
| US-20150056699-A1 | SMALL MOLECULE INDUCERS OF GDNF AS POTENTIAL NEW THERAPEUTICS FOR NEUROPSYCHIATRIC DISORDERS | GFRA1, GFRA2, GFRA3 | DRD4 101/4885DRD2 25/4885KDM4E 2385/4885 |
| US-20030008878-A1 | Benzimidazoles that are useful in treating sexual dysfunction | CYP19A1, CYP51A1, CYP17A1 | DRD4 2278/4885DRD2 2231/4885KDM4E 2948/4885 |
| US-20130018056-A1 | METHOD OF TREATMENT FOR MENTAL DISORDERS | DRD4, HTR4, SLC6A3 | DRD4 1/4885DRD2 6/4885KDM4E 826/4885 |
| US-20190022091-A1 | METHOD OF TREATMENT FOR MENTAL DISORDERS | DRD4, HTR4, SLC6A3 | DRD4 1/4885DRD2 6/4885KDM4E 826/4885 |
| US-20120115879-A1 | METHOD OF TREATMENT FOR MENTAL DISORDERS | DRD4, HTR4, SLC6A3 | DRD4 1/4885DRD2 6/4885KDM4E 826/4885 |
| US-20020169166-A1 | Benzimidazoles that are useful in treating sexual dysfunction | CYP19A1, CYP51A1, CYP17A1 | DRD4 2278/4885DRD2 2231/4885KDM4E 2948/4885 |
| US-20030162790-A1 | Benzimidazoles that are useful in treating sexual dysfunction | CYP19A1, CYP51A1, CYP17A1 | DRD4 2278/4885DRD2 2231/4885KDM4E 2948/4885 |
| US-20140107128-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | PDE5A, PDE3B, PDE3A | DRD4 53/4885DRD2 32/4885KDM4E 509/4885 |
| US-20080161566-A1 | Crystal and Salt of 1-Cyclopropylmethyl-4-[2-(3,3,5,5-Tetramethylcyclohexyl)Phenyl]Piperazine | ICAM1, IL5, VCAM1 | DRD4 2440/4885DRD2 2001/4885KDM4E 3062/4885 |
| US-20100216807-A1 | HETEROCYCLIC COMPOUNDS AS SEROTONERGIC AND / OR DOPAMINERGIC AGENTS AND USES THEREOF | HTR1A, HTR1B, HTR1D | DRD4 19/4885DRD2 6/4885KDM4E 4587/4885 |
| US-20140296247-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | CYP19A1, HSD17B11, SHBG | DRD4 282/4885DRD2 201/4885KDM4E 2970/4885 |
| US-20090005354-A1 | New Amino Derivatives and Their Use as Pharmaceuticals | DRD2, DRD1, DRD3 | DRD4 4/4885DRD2 1/4885KDM4E 2273/4885 |
| US-20050267096-A1 | New indazole and indolone derivatives and their use pharmaceuticals | DRD2, DRD3, DRD1 | DRD4 7/4885DRD2 1/4885KDM4E 2938/4885 |
| US-20050261291-A1 | 1,2-Di(cyclic)substituted benzene compounds | CCR10, HRH3, HRH2 | DRD4 566/4885DRD2 528/4885KDM4E 3582/4885 |
| US-20160129000-A1 | METHOD OF TREATMENT FOR MENTAL DISORDERS | DRD4, HTR4, SLC6A3 | DRD4 1/4885DRD2 6/4885KDM4E 826/4885 |
| US-20130072479-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | PDE5A, PDE3B, PDE3A | DRD4 45/4885DRD2 33/4885KDM4E 1507/4885 |
| US-20060276465-A1 | 1,2-di(cyclic) substituted benzene compounds | HRH3, CCR10, HRH1 | DRD4 532/4885DRD2 563/4885KDM4E 3905/4885 |
| US-20040198734-A1 | 2-(4-Aryl or heteroaryl-piperazin-1-ylmethyl)-1H-indole derivatives interacting with the dopamine | DRD2, DRD3, TPH1 | DRD4 6/4885DRD2 1/4885KDM4E 2002/4885 |
| US-20040110766-A1 | Benzimidazoles that are useful in treating sexual dysfunction | CYP19A1, CYP51A1, CYP17A1 | DRD4 2278/4885DRD2 2231/4885KDM4E 2948/4885 |
| US-20060183740-A1 | Novel salt form of a dopamine agonist | SLC6A3, CHRNA5, TACR2 | DRD4 21/4885DRD2 11/4885KDM4E 2433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.